Showing posts with label busi. Show all posts
Showing posts with label busi. Show all posts

Oct 22, 2014

Apple CEO discusses security with top Chinese official amid hacking claims: Xinhua

BEIJING Wed Oct 22, 2014 6:25am EDT
Apple Inc. CEO Tim Cook walks down a sidewalk during a break on the first day of the Allen and Co. media conference in Sun Valley, Idaho July 9, 2014. REUTERS/Rick Wilking
Apple Inc. CEO Tim Cook walks down a sidewalk during a break on the first day of the Allen and Co. media conference in Sun Valley, Idaho July 9, 2014.
Credit: Reuters/Rick Wilking
BEIJING (Reuters) - Apple Inc (AAPL.O) Chief Executive Tim Cook discussed user data security at a meeting on Wednesday with a top Chinese government official in Beijing, the official Xinhua news agency reported.
The meeting comes days after a Chinese web monitoring group published a report saying Apple users in China have been targeted in a sophisticated and widespread attack by hackers seeking private user data stored on the iCloud service.
The group, Greatfire.org, has alleged Chinese government involvement in the hack, a claim the government has strongly refuted. Apple has not issued any public statements on the matter.
At a meeting on Wednesday in Zhongnanhai, the Beijing complex housing China's central government, Cook and Vice Premier Ma Kai exchanged views on "protection of users' information" as well as "strengthening cooperation and in information and communication fields," according to Xinhua.
Greatfire told Reuters that Apple appeared to have rerouted user data on Tuesday to circumvent the hack.
The company did not respond to requests for comment Wednesday.
(Reporting by Gerry Shih)

View the original article here

Airbus Helicopters expects China to become biggest market by 2020

By Fang Yan and Matthew Miller
BEIJING Tue Oct 21, 2014 11:49pm EDT
A general view of an EC145 helicopter being assembled at the Airbus production facility in Donauwoerth, Southern Germany October 9, 2014. REUTERS/Michaela Rehle
A general view of an EC145 helicopter being assembled at the Airbus production facility in Donauwoerth, Southern Germany October 9, 2014.
Credit: Reuters/Michaela Rehle
BEIJING (Reuters) - Airbus Helicopters, the world's largest civil helicopter maker, expects China and Hong Kong to become its biggest global market within six years as Beijing starts to lift restrictions on the use of low altitude airspace from 2015.
The Airbus Group NV's (AIR.PA) helicopter division expects to increase its annual sales in China to 150 units by 2020 from around 30-40 helicopters now, its China president Norbert Ducrot told Reuters.
Sales in the United States, the firm's biggest market, average around 120-150 aircraft per year.
"The China market is very small with a big potential," Ducrot said in an interview in Beijing. "I am pretty sure around 2020, China will be the first market for Airbus Helicopters."
"Before (our customers) were mostly state companies, police and fire fighting, but now we can see the emergence of civil private helicopter operators," he added.
China simplified flight approval procedures for private aircraft late last year, but the fledgling market for helicopters and small aircraft has been constrained by the military's control of low altitude airspace.
A dearth of small airports, maintenance facilities, mechanics and pilots have also hampered the sector's growth.
Ducrot said he expects demand for helicopters and small aircraft to pick up gradually when China starts to open up its low altitude airspace next year.
As infrastructure improves and the military opens up more airspace by 2020, Ducrot estimates there will be 50,000 helicopters in China over the next 30 years. There are only about 330 helicopters currently in operation in China, including Hong Kong.
Other small plane makers are also expanding to cash in on China's growth potential.
Textron Inc's (TXT.N) Cessna Aircraft Company and Embraer SA (EMBR3.SA) have started assembling business jets in China, while Gulfstream Aerospace Corporation (GD.N) and Dassault Falcon (AVMD.PA) are adding service and maintenance centers in China.
Airbus Helicopters is currently the market leader in China, with customers that include state-backed Citic Offshore Helicopter Co Ltd 000099.SZ. In July, it announced an order for 123 helicopters to three privately owned Chinese general aviation companies, a deal that would effectively double the size of its fleet over the next five years.
In March, it also signed an agreement with Aivcopter, the firm's long-time government-owned partner, to jointly produce 1,000 EC175 models.
Industry observers say more than 200 general aviation companies, mostly privately owned, are lining up for regulatory approval in China.
Existing companies are also planning to expand their facilities. Beidahuang, China's biggest general aviation service provider, plans to buy over 40 planes and helicopters, increasing its fleet to around 130 by 2020.
(Reporting by Fang Yan and Matthew Miller in BEIJING; Editing by Miral Fahmy)

View the original article here

GLOBAL MARKETS-European shares fall as bank stress test worries offset ECB stimulus talk

* Efe says at least 11 banks to fail EU stress tests
* Sources say ECB considering buying corporate bonds
* Earnings results beat expectations in Europe, the U.S. (Recasts)
By Marius Zaharia
LONDON, Oct 22 (Reuters) - European shares slipped and the euro hit a one-week low on Wednesday as reports that at least 11 banks could fail a region-wide financial health check this weekend offset hopes of corporate bond buying by the ECB.
Spanish news agency Efe cited several unidentified sources saying three banks in Greece, three Italian lenders, two Austrian banks, as well as one bank each from Cyprus, Belgium and Portugal will fail the stress tests. The results of the checks, designed to see how banks would cope under adverse economic scenarios, are due on Sunday.
Spanish Economy Minister Luis de Guindos said he was confident Spanish lenders would do well.
The FTSEurofirst 300 index of top European shares was down 0.18 percent at 1,296.98 points.
"It is a dampener," said Beaufort Securities sales trader Basil Petrides of the Efe report, which reversed an upbeat start in European trading on better-than-expected company earnings and hopes of ECB corporate bond buying.
So far in Europe's earnings season, 9 percent of STOXX 600 companies have reported results, of which 65 percent have met or beaten profit forecasts, according to data from Thomson Reuters StarMine.
Swiss engineering group ABB, outdoor equipment maker Husqvarna and French carmaker PSA Peugeot Citroen were the latest to do so, while Heineken bucked the trend, reporting lower-than-expected sales.
European companies also got a lift after several sources told Reuters on Tuesday that the European Central Bank was considering buying corporate bonds on the secondary market and may make a final decision as soon as December with a view to beginning purchases early next year.
That would expand the private sector asset-buying programme the ECB began on Monday, with the aim of giving the euro zone economy a shot in the arm and safeguarding it from deflation, which has already gripped five of its 18 members.
The euro hit a one-week low of 1.26805 against the dollar, partly on the talk of more ECB activism.
"The general takeaway here for a lot of people is that it shows commitment from the ECB trying to find ways to expand its balance sheet. And also it shows ... the ECB wanting to pick up the pace," said Paul Robson, a currency strategist at RBS.
In Britain, the pound fell after Bank of England minutes showed policymakers were firmly against raising interest rates when they met earlier this month.
NERVES
The market moves were tentative as investors remain nervous about the state of the global economy, with the euro zone a particular soft spot. Such worries may intensify on Thursday when regional business surveys are due.
Later on Wednesday, traders will pay close attention to U.S. inflation data, due at 1230 GMT.
Economists expect annual core CPI inflation to stay flat at 1.7 percent in September, and a cooler reading would add to speculation that the Federal Reserve will wait longer before raising interest rates.
The consensus view is that the U.S. central bank will decide at its Oct. 28-29 policy meeting to wrap up its third round of asset purchases with new money, known as quantitative easing. But short-term interest rates futures imply markets do not expect the Fed to hike rates until late 2015.
Euro zone bond yields extended their falls on the back of the ECB's plans. German 10-year Bund yields, which set the standard for euro zone borrowing costs, fell 1 basis point to 0.86 percent. Peripheral bond yields fell by more.
"The news of bond buying had quite a beneficial effect on the non-German bond markets, for good reason, so spread narrowing was quite substantial and today there is still some after-effect of that," said KBC strategist Piet Lammens.
In other markets, oil edged further above $86 a barrel after an industry report showed a smaller-than-expected rise in U.S. crude inventories, extending a tentative recovery in the oil price from a four-year low.
Gold eased from six-week highs. (Additional reporting by Jemima Kelly and Michael Urquhart in London and Lisa Twaronite in Tokyo; Editing by Catherine Evans and Susan Fenton)

View the original article here

UPDATE 3-Drugmakers to join forces to make millions of Ebola vaccine doses

* J&J says has discussed collaboration with GlaxoSmithKline
* J&J investing up to $200 mln to accelerate programme
* Bavarian Nordic to receive cash injection from J&J (Recasts, adds comment on collaboration)
By Ben Hirschler
LONDON, Oct 22 (Reuters) - Leading drugmakers plan to work together to accelerate development of an Ebola vaccine and produce millions of doses of the most effective experimental product for use next year.
Johnson & Johnson said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain's GlaxoSmithKline, which is working on a rival vaccine.
The U.S. group's head of research Paul Stoffels said the two companies would support each other's work and could combine their vaccines if that made sense, while other companies without an Ebola treatment are ready to provide production capacity.
There is currently no proven vaccine against the deadly disease but several companies are racing to develop products. Clinical tests on GSK's vaccine and another from NewLink Genetics are under way, while human tests on J&J's vaccine will start in January.
The World Health Organization (WHO) hopes that tens of thousands of people in West Africa, including frontline healthcare workers, can start receiving Ebola vaccines from January as part of large-scale clinical trials.
"I have spoken with (GSK chief executive) Andrew Witty over the past few days several times as colleagues on how we are going to solve this," Stoffels told reporters. "It might even be that we have to combine their vaccine with ours."
J&J said the accelerated work on its Ebola vaccine, which has been helped by recent advances in technology, would yield 250,000 doses by May.
The company plans to test its vaccine for safety and immune response in healthy volunteers in Europe, the United States and Africa from early January, having committed up to $200 million to accelerate the programme.
BOOST FOR BAVARIAN NORDIC
West Africa's Ebola outbreak began in March and has killed more than 4,500 people, most of them in Liberia, Sierra Leone and Guinea, according to the WHO. Outbreaks in Senegal and Nigeria have been declared over by the WHO and there have been a handful of cases in Spain and the United States.
The J&J vaccine was discovered in collaboration with the U.S. National Institutes of Health (NIH) and includes technology from Denmark-based Bavarian Nordic, which will now receive a cash injection from the American healthcare company.
The total potential deal value for Bavarian Nordic could be more than $187 million, including upfront payments, milestone payments based on product progress, a supply contract and the purchase by J&J of shares in the Danish biotech business.
Bavarian Nordic's share price jumped 20 percent by 1045 GMT after the announcement of J&J's plans.
J&J has simplified and fast-tracked its vaccine programme in the light of the world's worst Ebola outbreak.
It had been working to develop a vaccine against both the Zaire and Sudan strains of Ebola, as well as a related condition called Marburg disease. However, it is now also developing a vaccine targeting only the Zaire strain behind the current epidemic, which should yield results faster.
PROMISING SIGN
Although the safety and effectiveness of J&J's and other experimental vaccines has yet to be proven, they have provided good protection against the Zaire strain of Ebola when tested on macaque monkeys, which is seen as a promising sign that they are likely to work in humans.
Like a number of experimental vaccines against various diseases, J&J's vaccine uses a common cold virus, called an adenovirus, to carry its payload.
Immunisation with the J&J vaccine, which was developed by its Crucell unit in the Netherlands, consists of two injections: one to prime the immune system and a second to boost the response. By contrast, researchers are testing a single shot of GSK's vaccine.
How safe and effective J&J's product will be in humans remains to be seen, but in clinical trials more than 1,000 people received similar vaccines from Crucell for other diseases with no apparent ill effects, offering some reassurance.
Bavarian Nordic, meanwhile, has used a similar approach in producing a smallpox vaccine that has been stockpiled around the world and tested on more than 7,000 people. (1 US dollar = 5.8566 Danish crown) (Additional reporting by Supriya Kurane in Bangalore; Editing by David Goodman)

View the original article here

Oct 16, 2014

AbbVie board ditches planned $55 billion Shire acquisition

By Ben Hirschler

LONDON Thu Oct 16, 2014 12:41pm EDT

A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid

A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014.

Credit: Reuters/Brendan McDermid

LONDON (Reuters) - U.S. drugmaker AbbVie (ABBV.N) has pulled the plug on its plan to buy Dublin-based Shire (SHP.L), recommending shareholders vote against the proposed $55 billion takeover following new U.S. tax rules.

Shire stands to be paid a break-up fee of about $1.64 billion, assuming AbbVie's shareholders follow the advice and reject the transaction.

The reversal -- which had been anticipated after Chicago-based AbbVie said it was reconsidering the deal -- hands a major scalp to the U.S. Treasury, which has been fighting to make tax-avoiding acquisitions more difficult.

That has hit the value of other potential takeover targets in Europe and cast a shadow over transactions that have yet to be completed.

But AbbVie's retreat could spark fresh deal-making by Shire, which has a strong track record of acquisitions to fuel its fast-growing business and may now look around to buy other companies, with its firepower boosted by the break-up fee.

The U.S. government's tax proposals are designed to make it harder for American firms to shift their tax bases out of the country and into lower cost jurisdictions in Europe.

"The agreed-upon valuation is no longer supported as a result of the changes to the tax rules and we did not believe it was in the best interests of our stockholders to proceed," AbbVie's chief executive Richard Gonzalez said in a statement.

AbbVie's move for Shire, a leader in drugs to treat attention deficit disorder and rare diseases, was announced in July amid a spate of deals in the pharmaceutical sector.

Gonzalez said at the time that the acquisition, involving the creation of a new U.S.-listed holding company with a tax domicile in Britain, was not just about tax.

But the firm said on Thursday that the changes in the U.S. tax regime "eliminated certain of the financial benefits of the transaction, most notably the ability to access current and future global cash flows in a tax efficient manner as originally contemplated in the transaction. This fundamentally changed the implied value of Shire to AbbVie in a significant manner."

Shire said it was considering the current situation and would make a further announcement in due course.

News on Wednesday that AbbVie was cooling to the transaction hammered shares in Shire, sending them down 22 percent to where they were before the deal talks emerged in June, and the shares were down a further 12 percent at 3,525 pence by 1145 GMT.

AbbVie's charge of heart has been a bombshell for some of the world's top hedge funds, which have lost out heavily on the Shire stock they were holding.

SHAREHOLDER MEETING

AbbVie said the withdrawal of its recommendation alone would not cause a lapse in the offer for Shire and it must convene a shareholder meeting before Dec. 14 to vote on the deal.

A spate of so-called tax inversion merger deals, particularly in healthcare, prompted the U.S. move to change tax regulations, including placing a ban on loans that allow U.S. firms to access foreign cash without paying U.S. tax.

AbbVie said the breadth and scope of the changes "introduced an unacceptable level of uncertainty to the transaction".

The company also took a swipe at the "unilateral" nature of the U.S. government's move and complained about "the unexpected nature of the exercise of administrative authority to impact longstanding tax principles".

AbbVie's second thoughts on the deal have surprised Shire investors, coming just weeks after Gonzalez, in the wake of the Treasury proposals, told employees of both companies he was "more energized than ever" about the transaction.

Aside from the tax benefits, buying Shire offered AbbVie a way to reduce reliance on arthritis treatment Humira, the world's top selling medicine, whose $13 billion in annual sales accounts for more than 60 percent of company revenue.

The episode has fueled doubts about whether Pfizer (PFE.N) will ever make another run at AstraZeneca (AZN.L), after abandoning a $118 billion bid in May. AstraZeneca shares fell 2.5 percent on Thursday, after losing ground on Wednesday.

Shares in Britain's Smith & Nephew (SN.L) and Switzerland's Actelion (ATLN.VX), also tipped as inversion targets, both fell a further 3 percent.

Tax experts say inversions are still possible but the U.S. action has cut their appeal, suggesting they will only make sense if there is a compelling strategic fit between two firms.

Two other U.S. drugmakers, Salix Pharmaceuticals (SLXP.O) and Auxilium Pharmaceuticals (AUXL.O), have already called off smaller inversion deals this month.

SHIRE'S OWN DEAL-MAKING

Analysts are now looking ahead to Shire's strategy as an independent company once again and its own potential for making acquisitions -- or else becoming a target for another company.

Before the AbbVie agreement, Shire Chief Executive Flemming Ornskov had made clear he was interested in buying assets and Jefferies analysts said a standalone Shire could now be poised to aggressively target acquisitions.

Shire itself might also be a target for other pharmaceutical companies less driven by tax considerations. Allergan (AGN.N), for example, which is fighting a bid from Valeant Pharmaceuticals International (VRTX.O), has approached Shire in the past.

(Additional reporting by Abhiram Nandakumar and Aurindom Mukherjee in Bangalore; Editing by Greg Mahlich, Pravin Char and Clara Ferreira Marques)


View the original article here

Top investors, strategists take pummeling in Wall St sell-off

By Svea Herbst-Bayliss

BOSTON Thu Oct 16, 2014 7:27am EDT

The Wall St. sign is seen outside the door to the New York Stock Exchange in New York's financial district February 4, 2014. REUTERS/Brendan McDermid

The Wall St. sign is seen outside the door to the New York Stock Exchange in New York's financial district February 4, 2014.

Credit: Reuters/Brendan McDermid

BOSTON (Reuters) - Some of Wall Street’s biggest names are licking their wounds as October lives up to its reputation as one of the market’s roughest months.

The Standard & Poor's 500 index  has now lost almost 8 percent in the past three-and-a-half weeks , wiping out almost all of the gains achieved earlier in 2014. What seemed like another good year for investors in U.S. equities is now fraught with uncertainty, with $1.3 trillion in S&P companies’ market value disappearing. Add in the impact of an oil price slump plus a big surprise rally in U.S. Treasuries, and the risks of big investment losses have risen dramatically.

From top equity strategists to big hedge funds and mutual funds, the carnage has spared few. Morgan Stanley strategists said this week that their model portfolio through Monday had trailed the S&P by 3.6 percentage points due to bad bets on technology stocks, including GT Advanced Technologies, the Apple supplier that surprised investors with a bankruptcy filing last week.

Billionaire investor Carl Icahn, had indicated for some time that he was prepared for a stock market reversal but it is unclear whether he would have been fully hedged against a 27 percent drop in the shares of online video company Netflix on Wednesday after it reported slower U.S. growth. Icahn's Icahn Enterprises owned 1.8 million shares at the end of the second quarter. He could not be immediately reached for comment.

The average U.S. equity mutual fund through Tuesday was down 2.3 percent on the year, according to Morningstar data, trailing the S&P, which is up a meager 0.8 percent. Meanwhile, leveraged ETFs, which try to double the performance of key averages, are doing worse – a popular leveraged bond ETF that bets on higher long-dated yields has lost 16 percent in the last 20 days. The Proshares Ultra S&P 500 fund – an ETF that looks to double the S&P’s performance  – is down 14 percent in 19 days.

Top equity strategists at major investment banks polled this year by Reuters have also been caught wrong-footed. They steadily boosted their bets on the rally continuing. The median S&P 500 year-end forecast has been steadily climbing, from a median of 1,925 in December 2013, to 2,000 in June, and then 2,033 in a Sept. 25 poll.

FEAR TOMORROW

Still, some investors fear there is a lot worse to come – and this time they are concerned that the U.S. Federal Reserve won’t be in a position to stem the selloff as it has done in recent years. The Fed is likely to be reluctant to engage in more quantitative easing, the pumping of money into the financial system through bond purchases."I fear tomorrow could be worse," said James Sanford, portfolio manager at SAG Harbor Advisors, adding that "while we haven't seen the swings we saw in 2011, some of the problems we had at that time are still with us and this time the cavalry in the form of the Fed isn't coming to save us."

To be sure, after a five-year bull market on Wall Street, many big-name investors cautioned that a pullback was long overdue. But the suddenness of the move has been an awakening for fund managers and strategists, many of whom had doubled down on their bullishness as the year wore on, steadily increasing bets on more gains in equities.

One of those was Dan Greenhaus, strategist at brokerage BTIG LLC, who lamented in a note on Tuesday evening that he was one of the Street’s last strategists to raise his S&P year-end target – to 2,100 on September 18, just before the market took a turn for the worse.

Greenhaus had expected weakness in equities at some point, but by September bought into the thesis that underperforming hedge funds would buy into the advance, leading to a "catch-up" trade. Greenhaus did not return calls seeking comment.

However, many hedge funds have run for cover at the first sign of trouble, adding to the sell-off's speed and intensity.

They've responded by exiting largely popular trades, particularly in energy stocks, that had become losers. Hedge fund favorite Cheniere Energy Inc tumbled 14.5 percent in five days, and Anadarko Petroleum Corp, another stock widely held by hedge funds, dropped 12.8 percent. Drugs company Gilead Sciences Inc, also popular with hedge funds, has lost 12.6 percent in five days.

    And then there are losses associated with failed deals including news that AbbVie is reconsidering its bid for biotech company Shire, possibly dealing a fresh blow to hedge fund titan John Paulson, who had a big bet on Shire and publicly praised the deal only a few weeks ago.

    Shire's value plunged more than 20 percent on Wednesday from around $49 billion to $39 billion, potentially wiping around $500 million from the value of Paulson's stake and $270 million off Elliott Management's stake, according to Reuters calculations.

    Credit Suisse Prime Services data show that hedge funds' most popular long positions fell 8.6 percent during the first nine days of October, compared with a 5 percent drop for the S&P 500.

    The bankruptcy of GT Advanced, which had a contract to supply Apple with sapphire glass, had a negative knock-on impact for many stocks, hedge fund managers say. Among its shareholders at the end of the second quarter were mutual fund giant Fidelity and many hedge funds including Whitebox, Highbridge Capital Management and Citadel.

    "Hedge funds are getting crushed right now," said Peter Rup, CEO and chief investment officer at Artemis Wealth Advisors, which advises high net-worth families and foundations. "They are notoriously bad at market turns and it is going to be a horrible month. They got a little lazy and didn't take preventative measures in time."

    Morgan Stanley chief equity strategist Adam Parker had also included GT in his list of favored stocks. His portfolio included a 1 percent allocation to GT. "Please forgive us," Parker wrote Tuesday of his bet on the stock, which has lost 93 percent of its value this year.

    Parker noted that his basket of stocks has trailed the S&P 500 through Oct. 13 by 3.6 percentage points due to weak stock selection in technology and financials and an overweighting in the consumer discretionary area. Recently added positions in stocks like software company VMware and casino company Las Vegas Sands have disappointed.

    Parker was not available for comment. His note points out that the portfolio has outperformed the S&P by 6.7 percentage points since the beginning of 2011.    

SOME BOND BETS SUCCEED   

    As anxiety about tumbling stocks spread, yields on the 10-year U.S. government bond dropped below 2 percent on Wednesday for the first time since mid-2013, underscoring just how nervous investors are.

    Risky leveraged exchange-traded funds that bet on rising bond yields clocked steep losses with the Proshares UltraShort 20+ year Treasury ETF losing 1.6 percent. The ETF has lost 16 percent in the last 20 trading days.

    Michael Landreville, who runs the Thrivent Government Bond Fund, braced for higher interest rates long ago and stocked his fund with bonds maturing years from now. But in light of the current market dislocation, he plans to shorten his duration. The fund lost 0.82 percent in September, but is up 3.38 percent on the year, according to Thrivent's web site.

    Low yields have rewarded bond fund managers who positioned their funds with long durations - that is, bonds whose prices rise more as yields fall - in 2014.

    One is the $238 million Wasatch-Hoisington U.S. Treasury Fund. Portfolio Manager Van Hoisington said he saw no signs of higher rates at the start of the year given high worldwide debt levels.

    "We felt the possibility of rising inflation was miniscule," he said. The fund has kept its effective duration around 20 years, helping it return 25.8 percent through Oct. 14. That beat 83 percent of its peers, according to Morningstar data, far above the 5.58 percent return for the Barclays U.S. Aggregate Bond index, which currently has a duration of 5.63 years.

    And not everyone was overly optimistic on equities. David Joy, chief market strategist at Ameriprise Financial in Boston, put a year-end target of 1,845 on the S&P 500, expecting weakness as the Fed backed away from its stimulus. However, he hadn't expected more of a decline than this – and is now questioning whether he has been bearish enough.

    "Now the wild card is, instead of talking about accelerating growth, we're talking about importing weakness from overseas, and I think this is more problematic for the market," he said.

(With additional reporting by Ross Kerber in Boston, Jennifer Ablan, Daniel Bases, David Gaffen, Richard Leong and Caroline Valetkevitch in New York; Editing by David Gaffen and Martin Howell)


View the original article here

Alibaba affiliate Alipay rebranded Ant in new financial services push

By Gerry Shih

BEIJING Thu Oct 16, 2014 5:50am EDT

Employees and journalists take pictures and videos of a giant electronic board showing the online transaction value on Alipay, an online payment system of China's leading e-commerce retailers Taobao.com and Tmall.com, at the parent company Alibaba's headquarters in Hangzhou, Zhejiang province November 11, 2013. REUTERS/China Daily

Employees and journalists take pictures and videos of a giant electronic board showing the online transaction value on Alipay, an online payment system of China's leading e-commerce retailers Taobao.com and Tmall.com, at the parent company Alibaba's headquarters in Hangzhou, Zhejiang province November 11, 2013.

Credit: Reuters/China Daily

BEIJING (Reuters) - Chinese e-commerce firm Alibaba Group Holding Ltd said on Thursday it has changed the name of its Alipay financial services affiliate to Ant Financial Services Group as it steps up its push into the financial services industry.

Alibaba has been aggressively offering new financial services around Alipay, including a money market fund for consumers, a mobile payment app and even a new private bank that was approved by the Chinese government in September.

Due to Alibaba's dominant market position in e-commerce, Alipay has emerged as the online payment processing leader in China. It clears 80 million transactions per day, including 45 million transactions through its Alipay Wallet mobile app, the company said on Thursday.

The rebranding of the Alipay unit, whose legal name is Zhejiang Ant Small and Micro Financial Services Group Co, is part of a strategy by Alibaba and its affiliated companies to accelerate development of financial business. The name 'Ant' was chosen to symbolize the potential strength of a number of smaller brands working together, executives said.

At a day-long presentation in Beijing, Ant Financial executives outlined a vision of turning its mobile payment app into a full-fledged, data-driven commercial platform. They have their sights set on a service where businesses can deliver personally tailored smartphone ads and promotions based on Alipay data gleaned from an individual consumer's shopping habits.

"China has never been lacking banks; it has 200 of them," said Ant Financial Chief Executive Lucy Peng. "But we have an opportunity to use Internet methods, Internet technology, Internet thinking to disrupt traditional finance."

UNIQUE POSITION

Alibaba controversially spun out Alipay in 2011, but its executives including executive chairman Jack Ma maintain control of the payment processor, considered by some analysts as one of the most valuable assets in the Alibaba universe due to its unique position in Chinese commerce.

The new Ant Financial umbrella will oversee six financial services entities that are affiliated with Alibaba, but were not part of the company that listed on the New York Stock Exchange last month in Alibaba's $25 billion initial public offering.

The six entities include: Alipay; Alipay Wallet; Yu'e Bao, a money market fund with 570 billion yuan ($93 billion) under management; Zhao Cai Bao, a third-party financial services platform; micro-loan provider Ant Micro; and MYBank, a private bank.

MYBank received approval from Chinese banking authorities in September, part of a pilot program launched earlier this year and the first tentative step by the country to open its closely guarded banking sector to private investors.

Alibaba stated in its IPO prospectus that given regulator approval, the Alipay affiliate could issue 33 percent of its shares to Alibaba in the future. Ant Financial executives on Thursday confirmed the terms, but said there were no new changes to the plans.

In response to a question, Peng said there are no current plans for Ant Financial to hold an initial public offering of its own.

(Reporting by Gerry Shih; Editing by Kenneth Maxwell)


View the original article here

Exclusive: Short seller Carson Block considers hedge fund management firm

By Jennifer Ablan and Sam Forgione

NEW YORK Thu Oct 16, 2014 4:23pm EDT

Carson Block, director of research and founding partner of Muddy Waters Research LLC, speaks during an interview in New York, October 16, 2014. REUTERS/Brendan McDermid

Carson Block, director of research and founding partner of Muddy Waters Research LLC, speaks during an interview in New York, October 16, 2014.

Credit: Reuters/Brendan McDermid

NEW YORK (Reuters) - Short seller Carson Block, the founder of research firm Muddy Waters LLC who has exposed accounting problems at a slew of Chinese companies, said on Thursday that he is seriously considering launching a hedge fund investment firm.

"We are more so than ever very seriously considering becoming a fund manager, but it would not be the same sort of Muddy Waters 8,000-page reports," Block said in an interview. "When you're running a fund management business, it takes a lot of resources to put those out."

Block said his hedge fund firm would combine activism with long-short strategies but with an emphasis on betting against companies.

Block became a rising star in the $3 trillion hedge fund industry after he publicly challenged the accounting practices of a series of Chinese companies that trade on North American stock exchanges, and then successfully bet against them by using his own money to short their stocks.

Block said his Muddy Waters firm, which consists of fewer than 10 employees, specializes in producing short-selling research that he distributes free of charge. The firm makes money by trading its principals' own capital, meaning Block puts his dollars behind his work.

"There have been companies that we felt would be good shorts, but they wouldn't really make good Muddy Waters activist report material, so we didn't short them, and we missed some opportunities there," Block said.

"So I think by having money under management, it would enable us to have more resources so that we could spend the right amount of time also managing that non-activist book and capitalizing on those opportunities," he added.

"Every time I've thought about it in the past, I've thought well, there are a lot of headaches with that, and I'm not accountable to anybody but myself at present, and that's a pretty strong allure, but there are arguments in favor of going toward a model where we're more resembling an activist hedge fund as well."

He said if he decided to launch a hedge fund, he would seek to raise more than $200 million in outside money.

To date, Block's most prominent takedown is of Sino-Forest Corp [SCLC.UL], whose shares slumped 74 percent before the Chinese tree plantation operator eventually filed for bankruptcy protection in March 2012.

The collapse forced hedge fund king John Paulson to book $105 million in losses on the stock. Paulson's firm also was sued by a prominent Miami investor, who claimed Paulson failed to conduct proper due diligence on Sino-Forest.

Block said he has "one to two activist campaigns" in the fourth quarter, but would not disclose the companies he is targeting. "We are awash in ideas," he said.

Block used to be based in Hong Kong but fully relocated to California after receiving death threats.

(Reporting by Jennifer Ablan and Sam Forgione; Editing by Diane Craft and Richard Chang)


View the original article here

Moynihan reshapes Bank of America for an era without big legal costs

By Peter Rudegeair

NEW YORK Thu Oct 16, 2014 1:19am EDT

Bank of America Chairman and Chief Executive Brian Moynihan speaks during the Institute of International Finance Annual Meeting in Washington October 10, 2014. REUTERS/Joshua Roberts

Bank of America Chairman and Chief Executive Brian Moynihan speaks during the Institute of International Finance Annual Meeting in Washington October 10, 2014.

Credit: Reuters/Joshua Roberts

NEW YORK (Reuters) - While Bank of America Corp (BAC.N) Chairman and Chief Executive Brian Moynihan has been working to end legal problems, he has also been quietly retooling the bank for a post-crisis world.

He has taken more direct control over the bank's retail business and shifted executives into new positions, sources familiar with the matter said. He has ordered officials at every level of the bank to think harder about how to sell more products to existing customers, a practice that many banks have tried but few have successfully executed.

Moynihan has also helped reshape the board, and his sway with directors only increased when he became chairman earlier this month, the sources said.

The broad changes that he has made signal that he is planning to remain at the bank for the long haul, a minimum of five years, they said.

Some investors have speculated that once Moynihan, a lawyer by training, was done with legal settlements linked to the 2008-2009 housing and financial crisis, he would head for the exits.

Sources at the bank said that notion was false. Key investors fully support Moynihan as well.

    "Brian has done a superb job of taking the B of A back to basics and clearing up the problems from the past," Warren Buffett, chairman and CEO of Berkshire Hathaway Inc (BRKa.N), wrote in an email to Reuters. "He is exactly the right CEO to move the company forward and has the ingredients in place to do so." Berkshire Hathaway owns Bank of America preferred stock and warrants to buy 700 million common shares.

Some media outlets have speculated that when Moynihan does leave, Tom Montag, chief operating officer, will be in pole position to take the CEO spot. The sources at the bank dismissed that speculation, noting that Montag, 57, is older than Moynihan, 55, and that Moynihan is inclined to groom younger successors.           

Results the bank posted on Wednesday underscore how much work Moynihan still has to do. The bank posted a $70 million loss for common shareholders, after setting aside an extra $5.6 billion to cover a settlement with the Department of Justice over shoddy bond mortgage underwriting.

That settlement is only the latest in a string: since 2010, Bank of America has agreed to pay more than $70 billion to resolve legal disputes and buy back bad mortgages linked to the financial crisis. The bank's total tally of settlements seems to rise every quarter, to the chagrin of investors.

While the bank is hopeful that the worst of the settlements is behind it, its latest results show that its challenges extend beyond legal costs. Its revenue is stagnant, having hovered around $21 billion per quarter since 2012.

Moynihan is trying to boost the top line by selling more products to existing customers. The bank is pitching credit cards and home equity loans to its checking account holders, and is talking to its corporate borrowers about treasury and retirement-planning services.

These are standard moves for the head of a retail bank, but Bank of America is trying to take them a little further. In early October, it began offering a rewards program nationally to customers who do more business with the bank. Some of the perks include discounted rates on mortgages and home equity loans and greater benefits on credit cards. That program was launched in a few markets in June in a pilot program.

BIGGEST PROFIT ENGINE

To help ensure that his strategy is being properly implemented, Moynihan began directly overseeing retail banking - Bank of America's biggest profit engine - earlier this year.

The heads of the retail banking group, Dean Athanasia and Thong Nguyen, had been reporting to David Darnell, a co-chief operating officer who oversaw all retail-facing businesses. In August, the bank said Darnell was becoming a vice chairman, and Athanasia and Nguyen, would instead report directly to the CEO.

Athanasia is co-leading the retail bank from Boston, a change for a group that had long been based in Charlotte, where Nguyen works.

Moynihan sees younger executives like Athanasia and Nguyen as among his possible successors, sources said, although there is no front-runner for that role.

Moynihan worked with Athanasia and Nguyen at FleetBoston, which Bank of America bought in 2004. Other FleetBoston executives have also been given top roles, including Terry Laughlin, who was chief risk officer until his appointment as president of strategic initiatives in April; Anne Finucane, the global chief strategy and marketing officer; and Christine Katziff, the bank's chief auditor.

While Moynihan has reshaped the executive ranks, he has also helped shape the board: Eight of the 14 current directors, including Moynihan, have joined since he became CEO in 2010. A ninth, Charles Gifford, was chairman and chief executive of FleetBoston.

(Reporting by Peter Rudegeair, Editing by Dan Wilchins and Ross Colvin)


View the original article here

Exclusive: Commerzbank settlement with U.S. postponed amid probe

By Karen Freifeld

NEW YORK Thu Oct 16, 2014 4:09pm EDT

The headquarters of the Commerzbank AG is pictured before the bank's annual news conference in Frankfurt February 13, 2014. REUTERS/Ralph Orlowski

The headquarters of the Commerzbank AG is pictured before the bank's annual news conference in Frankfurt February 13, 2014.

Credit: Reuters/Ralph Orlowski

NEW YORK (Reuters) - Commerzbank AG's (CBKG.DE) settlement with U.S. authorities over alleged sanctions violations has been postponed, possibly until the end of the year, as prosecutors seek to coordinate the resolution of a separate probe stemming from transactions at the German bank connected to the massive Olympus Corp (7733.T) accounting fraud, according to people familiar with the matter.

Commerzbank had been primed to settle with U.S. regulators and prosecutors by the end of September over its dealings with Iran and other countries under U.S. sanctions, Reuters has reported.

The sanctions settlement was expected to cost the bank about $650 million, people familiar with the deal have told Reuters, and the bank had been expected to enter into deferred prosecution agreements with prosecutors that would suspend criminal charges.

But the accord was put on ice after the Manhattan U.S. Attorney's office, which is not involved in the sanctions deal, looked into the bank's records in connection with the $1.7 billion accounting fraud at Japan's Olympus, said two sources who did not want to be identified. Other people with knowledge of the matter did not dispute the reasons for the delay.

The total amount for a coordinated settlement is now expected to cost Commerzbank more than $650 million, one of the two sources said, but the person did not provide a new estimate.

Media outlets have previously reported that a probe related to lax money-laundering controls could delay Commerzbank's sanctions related settlement, but the Olympus connection has not been revealed, nor the new target for a settlement date.

Representatives for the Manhattan U.S. Attorney's office and Commerzbank declined to comment.

The Olympus fraud is considered one of the biggest corporate scandals in Japan's history. In 2011, the camera and medical equipment maker admitted the company used improper accounting to conceal massive investment losses over more than a decade and restated years of financial results.

Commerzbank handled hundreds of millions of dollars of transactions connected to the fraud, court filings show, and Manhattan U.S. Attorney Preet Bharara began to investigate the bank's records and compliance with the Bank Secrecy Act, the two sources said.

The Bank Secrecy Act (BSA) is the United States' prime anti-money laundering law and requires monitoring and flagging suspicious transactions.

Authorities have connected a former banker at Commerzbank, Chan Ming Fon, to the Olympus accounting scheme. Chan pleaded guilty in U.S. District Court in Manhattan last year to conspiracy to commit wire fraud.

Chan worked at Commerzbank in Singapore until 2000, was at Societe Generale until 2004 and then formed his own company where he continued to work for former Olympus executives, according to a report commissioned by Olympus in 2011.

Chan is cooperating with the government, court filings show. His lawyer declined to comment.

Commerzbank in recent years has already been focused on improving its controls after it entered into an agreement in 2012 with the Federal Reserve Bank of New York to improve compliance with BSA/anti-money laundering laws and regulations.

 The New York branch still failed to maintain adequate controls, the Federal Reserve found last year, and issued a cease and desist order. It is not clear if the Fed action was related to the bank's activities with Olympus.

A spokeswoman for the Federal Reserve declined comment.

Authorities involved in the sanctions settlement view the BSA probe as coming "out of left field," one of the two sources said. But from the government's perspective, it doesn't make sense to resolve one case and a couple of months later, have another against the same bank, the person said.

Authorities want to consider a joint settlement that could come by the end of the year, the source said.

The authorities involved in the sanctions settlement are the Department of Justice, the U.S. Attorney in Washington, D.C., the Treasury Department, the Federal Reserve, New York's Department of Financial Services, and the Manhattan District Attorney. All declined to comment on the settlement.

In addition to the $650 million, Reuters has reported that New York’s Department of Financial Services, which is expected to get a little less than half the money, wants Commerzbank to fire a handful of employees involved with the alleged sanctions-related wrongdoing.

The inquiry into Commerzbank's activities with sanctioned entities began in 2010 with the Manhattan District Attorney's office, a different source said. Authorities have found that the bank allegedly stripped identifying information from incoming wires to avoid red flags that would have helped regulators police the transactions, Reuters has reported.

(Reporting by Karen Freifeld; Additional reporting by Aruna Viswanatha in Washington; Editing by Karey Van Hall and Lisa Shumaker)


View the original article here

Ackman: Lawyers have documents purported to show Allergan misled on Valeant

By Alastair Sharp and Allison Martell

TORONTO Thu Oct 16, 2014 4:05pm EDT

William Ackman, founder and CEO of hedge fund Pershing Square Capital Management, speaks to the audience about Herbalife company in New York, July 22, 2014. REUTERS/Eduardo Munoz

William Ackman, founder and CEO of hedge fund Pershing Square Capital Management, speaks to the audience about Herbalife company in New York, July 22, 2014.

Credit: Reuters/Eduardo Munoz

TORONTO (Reuters) - Billionaire investor William Ackman turned up the heat on Allergan Inc. on Thursday when he accused the Botox maker’s board of misleading investors to fend off a hostile takeover bid from Valeant Pharmaceuticals.

Ackman, whose hedge fund Pershing Square Capital Management is Allergan’s biggest shareholder, told reporters that his lawyers had seen documents that show Allergan’s board knowingly released misleading statements about Valeant.

"We've actually found evidence that will come out in the next few days of attempts at manipulating Valeant's stock price down," Ackman said, noting that he has not seen that evidence because it has been marked as "highly confidential."

Valeant's New York-listed shares climbed 3.6 percent in afternoon trading. They have lost about 6 percent in often volatile dealings since Valeant bid for Allergan in late April.

Allergan's shares edged up 0.7 percent.

Allergan declined to comment and Reuters could not independently verify Ackman's claim. Allergan executives have previously said the concerns they expressed about Valeant were based on their knowledge of the Canadian company and the industry.

In an unusual alliance, even by hedge fund industry standards, Ackman has been working with Valeant for months to push the Botox maker into selling itself to Valeant. Allergan has steadfastly refused, calling Valeant’s offer too low and looking for other partners to avoid a deal with Valeant.

"We believe they put those statements out, that they knew that they were false at the time they made them, and we have found evidence to that effect, that this was a conscious takeover defense strategy to malign Valeant and the company," Ackman said after speaking at a conference.

Pershing Square is expected to file court documents early next week related to Allergan's lawsuit, which accuses the hedge fund and Valeant of breaking insider trading rules, said a person familiar with the matter but not authorized to discuss it publicly.

It is not clear if those court documents will include the material that Ackman says exists about the Allergan board's alleged misleading of investors.

"I think it will come to light in the context of litigation," Ackman said, giving only a vague hint of when the material will be made public.

Sources familiar with Valeant and Pershing Square have hinted that the company might be willing to raise its bid for Allergan, possibly as soon as next week when Valeant is expected to release earnings which the company has signaled will be strong.

Ackman has lined up a list of other big investors who have called on Allergan to call a special meeting in December where the hedge fund manager is expected to try and replace Allergan board members with his own directors who might be more receptive to Valeant's overtures.

As the battle for Allergan drags on each side has ratcheted up the rhetoric.

In a letter to the Allergan board in September, Ackman accused them of having libeled Valeant and said he had complained to U.S. and Canadian regulators.

Separately, last month Valeant Chief Executive Officer Michael Pearson wrote to Allergan alleging that it was making "baseless attacks" about his company. Allergan Chief Executive David Pyott and lead independent director Michael Gallagher said at the time that the company relied on its knowledge of Valeant and of the industry to express concerns about Valeant's business model.

Valeant did not comment on Ackman's remarks.

Known for making big bets on companies including Canadian Pacific and General Growth Properties, Ackman has also relied on the media to press his points.

(Reporting by Alastair Sharp and Allison Martell, writing by Svea Herbst-Bayliss; additional reporting by Rod Nickel; Editing by Jeffrey Hodgson and Chizu Nomiyama)


View the original article here

Exclusive: Goldman Sachs in talks to acquire ETF provider IndexIQ - sources

By Jessica Toonkel

Thu Oct 16, 2014 3:25pm EDT

Goldman Sachs stall on the floor of the New York Stock Exchange is shown in this July 16, 2013 file photo. REUTERS/Brendan McDermid/Files

Goldman Sachs stall on the floor of the New York Stock Exchange is shown in this July 16, 2013 file photo.

Credit: Reuters/Brendan McDermid/Files

n">(Reuters) - Goldman Sachs Group (GS.N) is in discussions to acquire IndexIQ, a Rye Brook, New York-based exchange-traded fund provider, according to three sources familiar with the situation.

The deal, if finalized, would enable Goldman to introduce passively managed and actively-managed exchange traded funds within months.

A Goldman Sachs Asset Management spokeswoman declined to comment. A call and e-mail to Adam Patti, the chief executive of IndexIQ, was not immediately returned.

(Reporting By Jessica Toonkel; Editing by Diane Craft)


An artist's rendering shows a big-bodied, short-faced kangaroo called a sthenurine that lived in Australia from about 13 million years ago until about 30,000 years ago, in this undated handout. REUTERS/Brian Regal/Brown University/Handout via Reuters

A record-breaking pumpkin, New York's official snack and all the 'Friends' you can use. Amy Tennery picks coverage you may have missed.  Full Article 


View the original article here

Goldman's focus on bond trading pays off as profit soars

n">(Reuters) - Goldman Sachs Group Inc (GS.N) reported a 50 percent jump in quarterly profit as last month's pickup in bond market activity helped to boost trading revenue, showing that banks sticking with the notoriously volatile business can reap big rewards.

Goldman's fixed-income, currency and commodities (FICC) business, which once contributed about 40 percent of its revenue, has been on a declining trend since 2009 as new rules discourage banks from trading on their own account.

Several big banks have already scaled back their trading operations or quit the business altogether amid doubts about whether the industry will ever truly rebound.

But that has left Goldman and a few other banks, including JPMorgan Chase & Co (JPM.N), to pick up clients and take advantage of periods of market volatility such as that seen in September.

Goldman's revenue from bond-trading soared 74 percent to $2.17 billion in the third quarter as strong U.S. economic data, stimulus measures by the European Central Bank, and the surprise exit of trading superstar Bill Gross from giant bond-trading firm Pimco jolted what had been a listless market.

"It is a positive indication that the long drought on the trading floor may be nearing an end," said Chris Kotowski, an analyst with Oppenheimer & Co.

Goldman's FICC business - its biggest - contributed about 26 percent of overall revenue in the quarter, and its growth far outstripped gains made by JPMorgan, Citigroup Inc (C.N) and Bank of America Corp (BAC.N). Goldman's closest rival, Morgan Stanley (MS.N), reports on Friday.

Goldman's shares were down 2 percent at $173.63. Stocks have been sliding in recent days on worries about the health of the global economy, and bank shares have been hit hard.

The earnings handily beat market estimates. But some analysts questioned the quality of the beat, saying much of it was attributable to Goldman's investing and lending business, which bets the bank's own money, and that the performance was unlikely to be sustainable because of tougher regulations.

Revenue from the business rose 15 percent to $1.69 billion.

NO. 1 EQUITY UNDERWRITER

Goldman, also one of the biggest beneficiaries of the resurgence in equity capital markets this year, said revenue from equity underwriting rose 54 percent to $426 million.

The bank ranked No. 1 for both equity underwriting and advisory services in the first nine months of 2014, according to Thomson Reuters data, helped by its work on big deals including the $25 billion IPO of Alibaba Group Holding Ltd (BABA.N).

Chief Executive Lloyd Blankfein cited improving economic conditions for the bank's performance, but acknowledged that "conditions and sentiment can shift quickly."

Net income attributable to common shareholders rose to $2.14 billion, or $4.57 per share, from $1.43 billion, or $2.88 per share, a year earlier.

Analysts on average had expected earnings of $3.21 per share, according to Thomson Reuters I/B/E/S.

Total net revenue rose 25 percent to $8.39 billion.

Overall investment banking revenue, which includes M&A, and debt and stock underwriting, rose 26 percent to $1.46 billion.

Compensation expenses rose 18 percent, but fell as a proportion of revenue. Operating expenses increased 12 percent.

(Reporting by Tanya Agrawal and Lauren Tara LaCapra; Editing by Ted Kerr)

An artist's rendering shows a big-bodied, short-faced kangaroo called a sthenurine that lived in Australia from about 13 million years ago until about 30,000 years ago, in this undated handout. REUTERS/Brian Regal/Brown University/Handout via Reuters

A record-breaking pumpkin, New York's official snack and all the 'Friends' you can use. Amy Tennery picks coverage you may have missed.  Full Article 


View the original article here

New Tesco boss likely to sell assets to fund recovery plan

By Kate Holton, Simon Jessop and James Davey

LONDON Thu Oct 16, 2014 12:24pm EDT

Pedestrians walk past a Tesco store in Bow, east London August 29, 2014. REUTERS/Paul Hackett

Pedestrians walk past a Tesco store in Bow, east London August 29, 2014.

Credit: Reuters/Paul Hackett

LONDON (Reuters) - Just six weeks into his job, Tesco (TSCO.L) boss Dave Lewis must look at selling assets in Britain and abroad as he battles to raise funds to pull the world's No.3 grocer out of the deepest crisis in its 95-year history.

Trading at the British retailer has deteriorated to such an extent that its debt and ballooning pension deficit mean it could do with more cash. And that's even before it starts to consider the cost of a plan to revive sales.

Some analysts and investors think Lewis should take advantage of his status as a new arrival to ask shareholders for money, rather than selling off valuable businesses such as its stores in Thailand or customer data specialist Dunnhumby.

But a rights issue, which some think should top 3 billion pounds ($4.8 billion), could prove a hard sell when Tesco is in the midst of investigations into the discovery of a 250 million pound black hole in its accounts.

Plus, several investors want to see the recovery plan first.

"No rights issue without a detailed strategy and without first trying to sell non-core assets at good prices," said David Herro of investors Harris Associates, which recently cut its stake in Tesco to 1 percent from 3 percent.

Harris, which has $130 billion of assets under management, is not convinced Tesco will need a rights issue at all, unless UK operating profitability totally collapses.

Yet pressure is building on Tesco's finances. Its adjusted net debt of 6.6 billion pounds is now 3.2 times operating cash flow, way ahead of a company target of 2.5 times and likely to rise, according to Morgan Stanley. Its debt-to-equity ratio is 0.76 versus an industry median of 0.53, Reuters data show.

Meanwhile, its pension deficit is 3.2 billion pounds from 2.4 billion a year ago.

Those factors, plus plunging profits, mean credit ratings agencies have warned they could downgrade the firm. A one notch cut would leave Tesco a single notch above "junk" status.

"HUGE MISTAKE"

Once an apparently unstoppable engine of growth, Tesco started to hit problems in the late 2000s when it held back investment at home to spend on new operations in Asia and eastern Europe, and an expensive failure in the United States.

The mistakes cost it dear, as it was slow to respond to changes in shopping habits. Its big out-of-town stores lost favor as shoppers moved to buy more locally and online, while discounters Aldi and Lidl and upmarket chains Waitrose and Marks & Spencer (MKS.L) put the squeeze on the middle ground.

The crisis came to a head this year, with three profit warnings in 64 days and the discovery of the accounting mistake, leaving billionaire Warren Buffett to describe his near 4 percent stake in Tesco as a "huge mistake". He has since cut it.

HSBC analyst David McCarthy thinks Lewis should act quickly, and ask shareholders for at least 3 billion pounds to fight back against its main British rivals -- Wal-Mart's Asda (WMT.N), Sainsbury's (SBRY.L), and Morrisons (MRW.L).

He believes that could also block Sainsbury's from following a similar path as it too has come under trading pressure.

"With Tesco addressing some of its problems by using a rights issue, this would limit the ability of its competitors to go down a similar route to respond to a rebasing in profits," he said. "Investors should only back one horse in this race."

But a rights issue could be complicated by the accounting scandal. Lewis has had to suspend eight senior staff over the profit mis-statement and is grappling with an internal forensic investigation and a probe by Britain's financial regulator.

"When you go to London markets to raise capital you need all these things signed off," one banker with experience in London equity fundraisings told Reuters. "You wouldn't want to raise capital and then find out there were more holes."

Lewis is expected to update the market on Tesco's own investigation on Oct. 23 along with delayed first-half results.

Investors and analysts think he may use his first public presentation to lower profit forecasts again and announce a further dividend cut, following a reduction in August.

Major strategic decisions are likely to come later -- another reason why shareholders might be cool on a rights issue.

"Tesco needs to simplify the group by selling assets, strengthening the balance sheet and reinvesting into the core UK business," a top 20 investor said on the condition of anonymity.

"The most enhancing way (to strengthen the balance sheet) is to sell assets and not dilute shareholders with a rights issue."

That would follow the path taken by France's Carrefour (CARR.PA), which has listed or sold assets abroad to focus on the turnaround of its domestic business.

"A REAL CONUNDRUM"

Tesco's most lucrative non-core assets are its businesses in South Korea and Thailand. Morgan Stanley estimates the South Korean business, if listed, could be valued between 3.2 billion pounds and 4.9 billion pounds. It puts Thailand at between 4.3 billion pounds and 7.2 billion pounds.

Analysts are less optimistic around eastern European assets where there are few local players that might be buyers.

Morgan Stanley values Tesco's international operations, excluding Ireland, at between 10.2 and 17.3 billion pounds.

British assets Tesco could put on the block include Dobbies garden centers, and Dunnhumby, the consumer data company behind the Clubcard loyalty scheme.

Tesco Bank could also be listed, while the restaurant group Giraffe and a stake in British coffee chain Harris & Hoole could be sold. However, investors note that these could help draw customers back into stores.

A person familiar with the situation has told Reuters that Tesco is reviewing around 50 different options, including a rights issue and the sale of non-core assets.

Some decisions are already being made. Lewis has informed staff at the Blinkbox digital service it will either be sold or closed and the embarrassing revelation that the group had recently taken hold of its fifth corporate jet was met with the announcement that all would be sold.

However, asset sales are not a solution in themselves, and the risk is that Tesco sells high growth businesses to invest in more price cuts and promotions in Britain, which so far have done nothing to revive its fortunes.

"You have a real conundrum," one sector banker said. "Investing in prices and promotions is just money down the drain," he said of the highly competitive UK grocery market.

"Lewis has got so much on his plate, he will have to think about divestments. But the Asian businesses in particular are good -- is it a good time to sell a high growth business?"

(Additional reporting by Neil Maidment, Freya Berry, Emma Thomasson and Anjuli Davies; Editing by Mark Potter)


View the original article here

Strong data stops the bleeding on Wall Street

NEW YORK Thu Oct 16, 2014 4:15pm EDT

Traders work on the floor of the New York Stock Exchange October 16, 2014. REUTERS/Brendan McDermid

Traders work on the floor of the New York Stock Exchange October 16, 2014.

Credit: Reuters/Brendan McDermid

NEW YORK (Reuters) - U.S. stocks ended near flat after another choppy session on Thursday as economic data eased fears about the potential effect of a weakening global economy on the United States.

The Dow Jones industrial average .DJI fell 24.95 points, or 0.15 percent, to 16,116.79, the S&P 500 .SPX gained 0.26 points, or 0.01 percent, to 1,862.75 and the Nasdaq Composite .IXIC added 2.07 points, or 0.05 percent, to 4,217.39.

The Dow fell for a sixth straight session, matching a streak last seen in August 2013, but indexes closed well off their lows. The S&P fell as much as 1.5 percent earlier.

The Russell 2000 .TOY small-cap index rose more than 1 percent for a third straight session.

(Reporting by Rodrigo Campos; Editing by Nick Zieminski)


View the original article here

Chrysler recalls more than 900,000 vehicles globally in two actions

DETROIT Thu Oct 16, 2014 7:55am EDT

The Chrysler logo is seen outside the Chrysler auto dealer in Broomfield, Colorado October 1, 2014. REUTERS/Rick Wilking

The Chrysler logo is seen outside the Chrysler auto dealer in Broomfield, Colorado October 1, 2014.

Credit: Reuters/Rick Wilking

DETROIT (Reuters) - Chrysler Group on Thursday announced two global recalls of more than 900,000 cars and SUVs combined for problems that could cause fires.

Chrysler, a unit of Fiat Chrysler Automobiles (FCHA.MI), is recalling about 470,000 cars and SUVs globally from model years 2011 through 2014 and equipped with a 3.6 liter engine and a 160 amp alternator, according to the company and documents filed with the U.S. National Highway Traffic Safety Administration.

The alternator may suddenly fail, possibly causing a stall or fire and increasing the risk of a crash, according to the NHTSA documents.

The second recall covers about 437,000 Jeep Wrangler SUVs globally from model years 2011 through 2013 because of a fire risk, according to the NHTSA documents. They said water in the exterior heated power mirror electrical connector could cause an electrical short.

Chrysler said it was unaware of any injuries resulting from either problem. The automaker said one accident might have stemmed from the first problem, but had no reports of fire. It was not aware of any accidents from the second problem.

The repair for the first recall is still under development, according to the NHTSA documents. Chrysler plans to begin notifying owners of the recall on Nov. 28, according to the NHTSA documents.

Models affected in this recall include the Chrysler 300 sedan, Dodge Challenger and Charger cars, and Dodge Durango and Jeep Grand Cherokee SUVs. An estimated 434,581 of the recalled vehicles are in the United States, 16,080 in Canada, 2,335 in Mexico and 17,000 outside North America, Chrysler said.

The repair for the Wrangler recall, which should begin on Dec. 5, includes moving the exterior mirror power feed to a separate connector and adding a water shield, according to the NHTSA documents.

In that recall, an estimated 313,236 of the SUVs are in the United States, 39,627 in Canada, 5,685 in Mexico and 78,369 outside of North America, Chrysler said.

(Reporting by Ben Klayman in Detroit; Editing by Lisa Von Ahn)


View the original article here

Japan lawmakers say open to limits on casinos in push for bill's passage

TOKYO Thu Oct 16, 2014 12:22am EDT

A visitor plays pachinko at Dynam's pachinko parlour in Fuefuki, west of Tokyo June 19, 2014. REUTERS/Issei Kato

A visitor plays pachinko at Dynam's pachinko parlour in Fuefuki, west of Tokyo June 19, 2014.

Credit: Reuters/Issei Kato

TOKYO (Reuters) - Japan's pro-casino lawmakers have agreed to consider setting limits on Japanese nationals' entry to casinos, bowing to pressure from opponents who threatened to block a legalization bill unless it addressed issues such as gambling addiction.

Japan's parliament is expected in the coming weeks to discuss legislation that would be an essential first step to unlock a gaming market some analysts say will be worth tens of billions of dollars a year.

The revision would boost chances that the bill will be passed this year as proponents hope, although it is not yet clear whether enough anti-casino lawmakers will be persuaded to provide the support it needs in both houses of parliament.

"The government, for the purpose of preventing the negative effects of casino facilities by non-foreign visitors, will take necessary measures regarding admittance and capacity...," said the amended section to the bill, a draft of which was shown to reporters on Thursday.

The revision would avoid banning Japanese entry outright and limiting casinos to foreign tourists, pro-casino lawmakers said. Some Japanese media reports said such a ban might be adopted to ensure passage of the bill.

Prime Minister Shinzo Abe has said casino resorts would help the economy by boosting tourism. But market researchers say Japan's 128 million people would likely account for a majority of casino revenues and casino operators have said foreigner-only resorts could struggle to make a profit.

"From our standpoint, I will say that we will not be interested in Japan or any other country on a foreigners-only basis. We can't do that. Our business model won't allow it," Sheldon Adelson, CEO of the world’s largest casino operator Las Vegas Sands Corp, told analysts on a conference call on Wednesday.

Hiroyuki Hosoda, chairman of the pro-casino lawmakers' alliance, said the revision was in response to concerns over gambling addiction and money laundering. Such worries should not hold up the current bill, he said.

A second bill, set to be drafted next year if the current bill passes by year-end, would address specifics including possible entry fees or conditions for entry by locals, Hosoda said.

He told reporters the current priority was to set in motion the legalization process for a casino industry, stressing its importance to Japan's economy.

"With the manufacturing sector weakened, it's time for the Japanese to aim for economic growth through tourism," he said.

Abe has said he hopes casinos will be legalized in time for the 2020 Olympic Games. Analysts have said any delays in legislation will make that difficult.

(Reporting by Ritsuko Ando; Editing by Edmund Klamann)


View the original article here

Markets on edge after worst turmoil in four years

By Herbert Lash

NEW YORK Thu Oct 16, 2014 3:09pm EDT

A trader works on the floor of the New York Stock Exchange October 16, 2014. REUTERS/Brendan McDermid

1 of 3. A trader works on the floor of the New York Stock Exchange October 16, 2014.

Credit: Reuters/Brendan McDermid

NEW YORK (Reuters) - Crude oil prices fell to a four-year low before rebounding and global equity markets declined again on Thursday as investors fretted about world growth and a revived European debt crisis after a two-year slumber.

Fresh data indicating strength in the U.S. economy helped pan-world stock indexes pare losses that had exceeded 1 percent earlier and cut the bid for safe-haven government debt, driving up yields. On Wall Street the major indexes bounced between negative and positive territory, though the S&P 500 remained below its 200-day moving average of around 1,905.

Data showing that the number of Americans filing new claims for jobless benefits fell to a 14-year low last week and industrial output rose sharply in September also helped the dollar recover.

Corporate earnings will lead equity markets to turn around, said Dan Morris, global investment strategist at TIAA-CREF

"The reason for that is underlying earnings for S&P 500 companies. It's been pretty consistently upward, and we think it's going to go continually upward," Morris said. "The underlying fundamentals support a rebound."

Of the 63 companies in the S&P 500 that have reported results, 65.1 percent beat expectations, above a 20-year average but slightly lower than the past four quarters, Thomson Reuters data show. The blended revenue growth estimate is 4.1 percent.

MSCI's all-country world index .MIWD00000PUS fell 0.13 percent to 392.71, while the pan-European FTSEurofirst 300 .FTEU3 index closed down 0.49 percent at 1,245.78.

The Dow Jones industrial average .DJI fell 13.68 points, or 0.08 percent, to 16,128.06. The S&P 500 .SPX rose 2.75 points, or 0.15 percent, to 1,865.24, and the Nasdaq Composite .IXIC added 8.80 points, or 0.21 percent, to 4,224.12.

The dollar mostly recovered on the view that Wednesday's sell-off was overdone given the relative strength of the U.S. economy and the Federal Reserve's commitment to tighten monetary policy.

A disappointing auction of Spanish debt and data showing that deflation hit five peripheral euro zone countries in September underscored the relative health of the U.S. economy and the divergent outlook for Fed and European Central Bank policy.

The euro EUR= was last down 0.28 percent against the dollar at $1.2800. The euro hit an 11-month low against the yen, at 134.16 yen.

The dollar was last up 0.23 percent against the yen JPY= at 106.14 yen.

Brent and U.S. crude recovered. Brent has lost more than 28 percent since June. Losses have accelerated in October on signs the Organization of the Petroleum Exporting Countries has no plan to cut output.

Brent crude for November delivery LCOc1 settled 69 cents higher at $84.47 a barrel. Earlier it had dropped to $82.60 a barrel, the lowest level since November 2010.

U.S. crude CLc1 rose 92 cents to settle at $82.70 a barrel.

U.S. Treasuries prices fell. Benchmark 10-year notes US10YT=RR were down 16/32 in price to yield 2.1498 percent.

In Europe, Greek government bonds were the hardest hit, with 10-year yields rising to nearly 9 percent, while Spain missed its target at a bond auction due to weak demand from investors.

Yields on 10-year German Bunds rose to 0.819 percent, after slumping to a new low of 0.716 percent.

(Reporting by Herbert Lash in New York; Additional reporting by Marc Jones in London; Editing by Leslie Adler and Diane Craft)


View the original article here

U.S. factories help drive big gain in industrial output in September

WASHINGTON Thu Oct 16, 2014 10:05am EDT

Robotic arms spot welds on the chassis of a Ford Transit Van under assembly at the Ford Claycomo Assembly Plant in Claycomo, Missouri April 30, 2014. REUTERS/Dave Kaup

Robotic arms spot welds on the chassis of a Ford Transit Van under assembly at the Ford Claycomo Assembly Plant in Claycomo, Missouri April 30, 2014.

Credit: Reuters/Dave Kaup

WASHINGTON (Reuters) - U.S. industrial production posted the biggest gain in nearly two years in September as factory activity quickened and utilities output logged a big-weather related jump, a welcome sign on the pace of the economy's recovery.

Output at the nation's mines, factories and utilities increased 1.0 percent after slipping 0.2 percent in August, the Federal Reserve said on Thursday. It was the biggest rise since November 2012 and handily outstripped the 0.4 percent gain expected on Wall Street.

With activity quickening, the amount of productive capacity in use rose to 79.3 percent, the highest level since June 2008. The Fed keeps an eyes on capacity use for signs inflationary bottlenecks may be developing. Despite the latest jump, the figure still remains 0.8 percentage point below its long-run average.

Manufacturing production, which had dropped 0.5 percent in August, advanced by 0.5 percent in September with widespread gains across subsectors. Economists polled by Reuters had expected a gain of just 0.3 percent.

Output at utilities rose 3.9 percent last month, an increase the Fed pinned on high demand for air conditioning as temperatures swung from below normal to above normal.

Mining production advanced 1.8 percent.

(Reporting by Timothy Ahmann; Editing by Andrea Ricci)


View the original article here

Data show U.S. economy's pulse is still strong

By Jason Lange

WASHINGTON Thu Oct 16, 2014 2:28pm EDT

Job seekers with visual impairments and potential employers talk at the fourth Annual Job Fair for Individuals with Visual Impairments in Cambridge, Massachusetts October 16, 2014. REUTERS/Brian Snyder

1 of 2. Job seekers with visual impairments and potential employers talk at the fourth Annual Job Fair for Individuals with Visual Impairments in Cambridge, Massachusetts October 16, 2014.

Credit: Reuters/Brian Snyder

WASHINGTON (Reuters) - The number of Americans filing new claims for jobless benefits fell to a 14-year low last week and industrial output rose sharply in September, positive signals that could help ease fears over the economic outlook.

Initial claims for state unemployment benefits dropped 23,000 to 264,000, the lowest level since 2000, the Labor Department said on Thursday.

A separate report from the Federal Reserve showed production at the nation's factories, mines and utilities advanced a larger-than-expected 1.0 percent last month, the biggest gain since November 2012.

The data offered evidence the economy remained on solid ground, with the labor market gaining steam. Investors in recent days have come to the view that slowing growth overseas will weigh on the U.S. economy and force the Fed to delay a hike in interest rates.

Weak retail sales data on Wednesday shook investor confidence and helped fuel a global sell-off in stock markets that continued on Thursday. U.S. stock markets were trading sharply lower.

The jobless claims report nonetheless reinforced expectations that slack in the labor market was being reduced.

"Have we achieved full employment? Not yet. Are we getting closer? Absolutely," said Stephen Stanley, an economist at Amherst Pierpont Securities.

It's possible some of last week's drop in claims was related to America's Columbus Day holiday, which may have affected how the Labor Department adjusts the data for seasonal swings, economists at RBS said in a note to clients.

The government, however, said there were no unusual factors in the report, while the four-week moving average of claims, which irons out week-to-week volatility, also fell to its lowest level since 2000.

OASIS OF PROSPERITY?

A Reuters poll published on Thursday showed economists still clinging to the view that the Fed would raise benchmark borrowing costs from near zero in the second quarter of next year despite mounting signs of weakness overseas. [ECILT/US]

The poll, however, was largely complete before the latest stock market sell-off, which has been accompanied by a big shift in investor expectations for the path of U.S. monetary policy. Interest rates futures are now pointing to a rate hike in October 2015.

St. Louis Federal Reserve Bank President James Bullard said in a television interview with Bloomberg that the U.S. central bank might want to keep its bond-buying program running for longer than anticipated given a drop in inflation expectations.

For now, at least, the U.S. economy is motoring ahead, with economists still expecting third-quarter growth to come in at around a 3 percent annual rate, a view buttressed by the pickup in industrial output.

The Fed pinned part of the gain to unusual weather that boosted air conditioning use, but there was also a broad-based increase in factory output, which grew a solid 0.5 percent.

A third report from the Fed's Philadelphia branch showed slowing growth in factory activity in the mid-Atlantic region.

(Reporting by Jason Lange and Tim Ahmann; Editing by Paul Simao)


View the original article here